Congestive heart failure/transplant- specifically congenital heart disease patients. We are currently investigating outcomes (morbidity and mortality) of congenital heart disease patients evaluated for heart transplants as well as variables that predict candidacy for transplant and transplant outcomes.
Chest pain. Multiple abstracts and pending review article on acute chest pain in patients presenting to the emergency department, specifically without prior diagnosis of coronary artery disease.
CHF readmission. Evaluating causes of heart failure readmission and patients at greatest risk. This includes patients with sleep disordered breathing.
Currently seeing patients with both systolic and diastolic heart failure, that are pre- and post-heart transplant as well as patients with pulmonary hypertension of various etiologies.
As a heart failure specialist I also manage patients on mechanical circulatory support devices such as left ventricular assist devices, perform right heart catheterizations with endomyocardial biopsies, and round in the UPMC Presbyterian CCU.
Involved in medical student curriculum development for congestive heart failure component of the MS-2 cardiology course and the MS-4 pathophysiology and pharmacology of heart failure course.
Ongoing education in the cardiology fellowship, including lectures on hemodynamics and evaluation and management of decompensated heart failure.
- MD, University of Rochester Medical Center, 2002
- Residency, University of Pittsburgh Medical School, 2006
- Fellowship, University of Pittsburgh Medical School, 2015
Education & Training
Ibrahim J, Fabrizio C, Sezer A, Thoma F, Boyle B, Mulukutla SR, Huston JH, Simon MA, Hickey GW. Beta blockers are associated with lower all-cause mortality among HFpEF patients. Clin Res Cardiol. 2024 Jun;113(6):951-958. PMID: 38695899.
Sicke M, Modi S, Hong Y, Bashline M, Klass W, Horn E, Hansra BS, Ramanan R, Fowler J, Sumzin N, Rivosecchi RM, Chaudhary R, Ziegler LA, Hess NR, Agrawal N, Kaczorowski DJ, Hickey GW. Cardiogenic shock etiology and exit strategy impact survival in patients with Impella 5.5. Int J Artif Organs. 2024 Jan;47(1):8-16. PMID: 38053245.
Bashline MJ, Rhinehart Z, Kola O, Fowler J, Kaczorowski D, Hickey G. Impella 5.0 is associated with a reduction in vasoactive support and improves hemodynamics in cardiogenic shock: A single-center experience. Int J Artif Organs. 2022 May;45(5):462-469. PMID: 35365048.
Smith NF, Salehi Omran S, Genuardi MV, Horn ET, Kilic A, Sciortino CM, Keebler ME, Kormos RL, Hickey GW. Primary Graft Dysfunction in Heart Transplant Recipients-Risk Factors and Longitudinal Outcomes. ASAIO J . 2022 Mar 1;68(3):394-401. PMID: 34593684
Pham R, McQuade C, Somerfeld A, Blakowski S, Hickey GW. Palliative Care Consultation Affects How and Where Heart Failure Patients Die. Am J Hosp Palliat Care. 2021 Jul;38(7):807-811. PMID: 33016083.
- OME International Research Award, 2003
- Am Soc Nuclear Cardiology Astellas Travel Award, 2013
- AHA Clin Research Presentation, 3rd Place, 2014
- Clinical Science Research Oral Pres, 3rd Place, 2014
- American Society of Transplantation (AST) Travel Award, 2014
